• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Oral Health Pavilion Set for Center Stage at HLTH 2024

    9/24/24 10:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care
    Get the next $HSIC alert in real time by email

    CareQuest Innovation Partners, Colgate-Palmolive Company, Henry Schein, and PDS Health partner to spotlight oral health's connection to overall health at the leading health industry event

    Showcasing the growing importance of the connection between oral health and overall health, four industry-leading companies are premiering a first-of-its-kind Oral Health Pavilion at HLTH 2024. CareQuest Innovation Partners, Colgate-Palmolive Company, Henry Schein, and PDS Health are partnering to create an experience that spotlights innovation in clinical practice and the importance of preventive self-care. HLTH attendees will experience the dental practice of the future that includes critical components of medical-dental integration, illustrating how medical and dental professionals can collaborate to improve patient care.

    "Introducing the first Oral Health Pavilion at HLTH is a significant step toward integrating dental and medical care, which can enhance both health equity and patient outcomes," said Denise Marks, chief financial officer and executive vice president at CareQuest Institute for Oral Health. "Addressing the gap in oral health innovation presents a crucial opportunity for health innovators to develop comprehensive solutions, making them more attractive to investors. We can drive meaningful progress in the health care industry by recognizing the proven link between oral health and overall health."

    Research increasingly highlights the benefits of integrated care, showing that it can help reduce costs and improve patient outcomes. Ensuring oral health is part of that care is critical, as 90% of all systemic diseases have oral manifestations.

    The Oral Health Pavilion will take attendees through various stages of a patient's oral health journey, which can include minimally invasive treatment options and simple at-home solutions. Health care professionals from multiple specialties can discover new ways to integrate oral health into general health care practices, improving overall patient wellness and care efficiency.

    Leaders from all organizations are looking forward to showcasing unique solutions that drive medical-dental integration and show the connection between oral health and overall health:

    • "At Colgate-Palmolive, we are committed to our purpose as a caring, innovative growth company that is reimagining a healthier future for all," said Dr. Maria E. Ryan, executive vice president and chief clinical officer, Colgate-Palmolive. "And with the Colgate brand in more homes than any other, we continue to inform consumers through educational programs about the importance of oral health to overall health and well-being. Improvements in oral health literacy can change knowledge, attitudes and oral health practices. We are thrilled to be part of HLTH's first-ever Oral Health Pavilion, along with our partners, to lead the way in advancing oral health education, self-care, medical-dental integration and innovation."
    • "Henry Schein has long believed that integrated care models focusing on prevention and wellness are essential to improving population health, making care more accessible, and reducing health care expenses," said Stanley M. Bergman, Chairman and CEO of Henry Schein. "To advance this vision, our existing oral health workforce is fully capable of performing regular screenings within the existing standard hygiene workflow — including blood pressure monitoring, basic point of care diagnostics, and vaccinations — and then helping patients to coordinate care with other members of the primary health care community. By reimagining the patient services offered during a dental visit, we can relieve access barriers and create a more efficient health care system."
    • "Integrating dental and medical care is essential to improving patient outcomes and reducing overall health care costs," said Stephen E. Thorne IV, founder and CEO of PDS Health. "Too many people still lack access to essential dental services, despite the proven link between oral health and overall health. By bringing dentistry to the forefront of the health care conversation, we not only recognize oral health care providers as key members of the primary care team but also emphasize the importance of early detection of systemic diseases through regular dental visits. This approach helps break down barriers to access and makes comprehensive, integrated care a reality for everyone."

    CareQuest Innovation Partners will also showcase innovative startups that participated in its SMILE Health accelerator, including the 2024 cohort: DentKits, DifferentKind, OraLiva, ThriveLink, Umayana, and Yumlish. Each company will provide an inside look at its innovation — from novel oral wound healing therapies and salivary diagnostics to AI-enabled bots for health service enrollment and at-home dentures — during a "Demo Day" event on Tuesday, October 22 at 1:30 p.m. on the startup stage.

    Representatives from the Oral Health Pavilion will also speak on industry panels, including:

    • Say Ahh! Panel, Monday, October 21, 10:40–11:20 a.m., Bold Stage: Moderated by Dr. Myechia Minter-Jordan, senior advisor of the CareQuest Institute for Oral Health, industry partners Stephen Thorne, founder and CEO of PDS Health, and Dr. Maria E. Ryan, EVP and chief clinical officer of Colgate-Palmolive will join Sarah Chavarria, chief executive officer and president of Delta Dental of California to discuss the importance of a holistic approach to health care that includes oral health as a fundamental component.
    • Here, There, Primary Care, Monday, October 21, 2:20–3 p.m., Rocket Stage: David Kochman, chief corporate affairs officer for Henry Schein, will join Colleen Lindholz, president, Kroger Health, Misha Palecek, chief transformation officer, DaVita, and Kameron Leigh Matthews, chief health officer at Cityblock Health to discuss current primary care concerns and potential solutions including AI, expanded roles for PAs and nurse practitioners, and integrated and innovative care models.

    Live demonstrations of the solutions that enhance the oral-medical integration will be held throughout HLTH in the Oral Health Pavilion.

    About CareQuest Innovation Partners

    CareQuest Innovation Partners® validates and scales transformative solutions to improve overall health through oral health. Together, with our ecosystem of leading industry partners, startups, and investors we make health care more accessible, equitable, and integrated. Joined by the shared mission to improve the oral health of all, CareQuest Innovation Partners is the for-profit subsidiary of CareQuest Institute. To learn more, visit carequestinnovation.com and follow us on Twitter and LinkedIn.

    About Colgate-Palmolive Company

    Colgate-Palmolive Company is a caring, innovative growth company that is reimagining a healthier future for all people, their pets and our planet. Focused on Oral Care, Personal Care, Home Care and Pet Nutrition, we sell our products in more than 200 countries and territories under brands such as Colgate, Palmolive, elmex, hello, meridol, Sorriso, Tom's of Maine, EltaMD, Filorga, Irish Spring, Lady Speed Stick, PCA SKIN, Protex, Sanex, Softsoap, Speed Stick, Ajax, Axion, Fabuloso, Murphy, Soupline and Suavitel, as well as Hill's Science Diet and Hill's Prescription Diet. We are recognized for our leadership and innovation in promoting sustainability and community wellbeing, including our achievements in decreasing plastic waste and promoting recyclability, saving water, conserving natural resources and improving children's oral health through the Colgate Bright Smiles, Bright Futures program, which has reached approximately 1.7 billion children and their families since 1991. For more information about Colgate's global business and how we are building a future to smile about, visit www.colgatepalmolive.com.

    About Henry Schein, Inc.

    Henry Schein, Inc. (NASDAQ:HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 25,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

    Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our distribution centers.

    A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. The Company's sales reached $12.3 billion in 2023, and have grown at a compound annual rate of approximately 11.5 percent since Henry Schein became a public company in 1995.

    For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, Instagram.com/HenrySchein, and @HenrySchein on X.

    About PDS Health

    PDS Health TM continues the journey started by Pacific Dental Services® in 1994, with a vision to redefine health care through the integration of dental and medical services. Its approach, centered on the connection between oral health and overall health, aims to create healthier, happier patients and set new benchmarks in the healthcare industry. As a leading provider of integrated healthcare support, the company delivers a broad spectrum of services to dental, dental specialties, and medical providers, enhancing operations and care delivery for clinicians across the U.S. For more information about PDS Health and its vision, visit pdshealth.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240924046672/en/

    Get the next $HSIC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSIC

    DatePrice TargetRatingAnalyst
    2/23/2026$100.00Neutral → Outperform
    Robert W. Baird
    12/9/2025$86.00Overweight
    Barclays
    8/26/2025$83.00In-line → Outperform
    Evercore ISI
    7/25/2025$75.00Buy → Hold
    Stifel
    7/14/2025$72.00Outperform → Neutral
    Robert W. Baird
    2/14/2025$80.00Equal Weight
    Wells Fargo
    1/6/2025$69.00 → $84.00Underperform → Buy
    BofA Securities
    12/4/2024$75.00Neutral
    Mizuho
    More analyst ratings

    $HSIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, CEO Bergman Stanley M sold $2,518,741 worth of Common Stock par value $0.01 per share (31,134 units at $80.90) and sold $1,463,592 worth of shares (17,997 units at $81.32), decreasing direct ownership by 3% to 309,092 units (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    2/27/26 4:31:42 PM ET
    $HSIC
    Medical Specialities
    Health Care

    CEO, Global Dist. & Tech. Albertini Andrea covered exercise/tax liability with 2,032 shares, decreasing direct ownership by 3% to 65,900 units (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    12/11/25 4:14:33 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form 4 filed by Large owner Kkr Hawaii Aggregator L.P.

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    12/9/25 9:05:50 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy

    Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company's peer-reviewed randomized controlled trial.CMS Payment Rate: $300 national Medicare payment rate established, effective January 1, 2026.Physician Perspective: New interview with Gastroenterologist Dr. Dak Patel about inFoods IBS in clinical use now available at https://investors.biomerica.com/events-and-presentations/default.aspx IRVINE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), an innovator in diagnostic-guided therapy, today announced respo

    2/26/26 8:19:00 AM ET
    $BMRA
    $HSIC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical Specialities

    Henry Schein Reports Fourth Quarter and Full Year 2025 Financial Results and Introduces 2026 Financial Guidance

    Q4 2025 GAAP diluted EPS of $0.85, compared to $0.74 GAAP diluted EPS in Q4 2024 Q4 2025 non-GAAP diluted EPS of $1.34, compared to $1.19 non-GAAP diluted EPS in Q4 2024 2026 non-GAAP diluted EPS expected to be in the range of $5.23 to $5.37, with total sales growth expected to be 3-5% Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the fourth quarter ended December 27, 2025. "Our fourth-quarter sales reflect continuing momentum resulting in the highest sales growth in 15 quarters. We are pleased with the sales results across all our businesses, particul

    2/24/26 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein One Launches Image Verify, Another Transformative Step Towards Achieving the Cleanest Claims in the Industry

    New Native, AI-Embedded Capability in Dentrix and Dentrix Ascend Helps Improve Image Quality Control at Capture Henry Schein One, the market leader in dental practice management systems, today announced the launch of AI-driven Image Verify, the latest innovation in a rapid series of product advancements designed to deliver the cleanest claims experience in dentistry. Image Verify, natively embedded in Dentrix and Dentrix Ascend, represents another major step towards the company's bold Clean Claims vision – a future where dental practices submit claims once and never have to touch them again. As the market leader in dental cloud-based technology, Henry Schein One has accelerated developm

    2/19/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    SEC Filings

    View All

    SEC Form 10-K filed by Henry Schein Inc.

    10-K - HENRY SCHEIN INC (0001000228) (Filer)

    2/24/26 4:42:20 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - HENRY SCHEIN INC (0001000228) (Filer)

    2/24/26 6:14:45 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form 8-K filed by Henry Schein Inc.

    8-K - HENRY SCHEIN INC (0001000228) (Filer)

    1/12/26 7:00:12 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Daniel William K bought $670,800 worth of shares (10,000 units at $67.08) (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/11/25 4:26:33 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Henry Schein upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded Henry Schein from Neutral to Outperform and set a new price target of $100.00

    2/23/26 8:29:17 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Barclays initiated coverage on Henry Schein with a new price target

    Barclays initiated coverage of Henry Schein with a rating of Overweight and set a new price target of $86.00

    12/9/25 8:50:15 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Henry Schein from In-line to Outperform and set a new price target of $83.00

    8/26/25 8:13:41 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Henry Schein Inc.

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    11/13/24 3:30:01 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Henry Schein Inc.

    SC 13G - HENRY SCHEIN INC (0001000228) (Subject)

    11/12/24 9:32:27 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Henry Schein Inc. (Amendment)

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    2/14/24 11:18:57 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Financials

    Live finance-specific insights

    View All

    Henry Schein Reports Fourth Quarter and Full Year 2025 Financial Results and Introduces 2026 Financial Guidance

    Q4 2025 GAAP diluted EPS of $0.85, compared to $0.74 GAAP diluted EPS in Q4 2024 Q4 2025 non-GAAP diluted EPS of $1.34, compared to $1.19 non-GAAP diluted EPS in Q4 2024 2026 non-GAAP diluted EPS expected to be in the range of $5.23 to $5.37, with total sales growth expected to be 3-5% Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the fourth quarter ended December 27, 2025. "Our fourth-quarter sales reflect continuing momentum resulting in the highest sales growth in 15 quarters. We are pleased with the sales results across all our businesses, particul

    2/24/26 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein to Webcast Fourth Quarter 2025 Conference Call on Tuesday, February 24, 2026, at 8:00 A.M. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that it will release its fourth quarter 2025 financial results before the stock market opens on Tuesday, February 24, 2026, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on the Henry S

    1/22/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Reports Record Third Quarter 2025 Financial Results and Raises Full Year Non-GAAP EPS Guidance

    Q3 2025 GAAP diluted EPS of $0.84, compared to $0.78 GAAP diluted EPS in Q3 2024, and Q3 2025 non-GAAP diluted EPS of $1.38, compared to $1.22 non-GAAP diluted EPS in Q3 2024 Raises 2025 guidance for non-GAAP diluted EPS to $4.88 to $4.96 and sales growth to 3-4% to reflect third quarter results Announces value creation initiatives expected to deliver over $200 million of operating income improvement over the next few years Agreement reached to provide KKR the right to increase its HSIC stock ownership up to 19.9% Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results

    11/4/25 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Leadership Updates

    Live Leadership Updates

    View All

    Henry Schein Enters Exclusive Distribution Agreement for CytoChip's CLIA-Waived Hematology Analyzer

    Partnership Expands Access to FDA-Cleared CitoCBC® System Across the U.S. Henry Schein, Inc. (NASDAQ:HSIC) has entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC® system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115495488/en/CLIA Waived CitoCBC System Des

    1/15/26 10:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Names Frederick M. Lowery as Chief Executive Officer

    Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. This press release features multimedia. View the full release here: https://www.businesswire

    1/12/26 7:00:00 AM ET
    $HSIC
    $TMO
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Stanley M. Bergman to Retire as Henry Schein's Chief Executive Officer at the End of 2025

    Mr. Bergman to Continue to Serve as Chairman of the Board Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that Stanley M. Bergman will retire as Chief Executive Officer (CEO) at the end of the year after 45 years at the Company, including more than 35 years as CEO. Mr. Bergman will continue to lead Henry Schein in his current role until his retirement and will remain as Chairman thereafter. The Board is commencing a formal search process in conjunction with a nationally recognized executive search firm and will consider internal and external candidates. "With the progress made advan

    7/15/25 7:05:00 AM ET
    $HSIC
    Medical Specialities
    Health Care